儿童呼吸道合胞病毒疾病负担及不同免疫策略的潜在效果:英格兰的建模与成本效果分析
该研究通过多变量回归分析估计英格兰5岁以下儿童呼吸道合胞病毒(RSV)疾病负担,并评估针对婴儿、孕妇或新生儿预防性抗体等不同免疫策略的成本效果。结果显示RSV每年每100名5岁以下儿童导致12次初级保健就诊和0.9次住院,负担主要集中于6月龄以下婴儿;最具成本效果的策略是选择性免疫所有在RSV流行季开始前出生的儿童,疫苗最高价格为220英镑(95%不确定性区间208-232),增量成本效果比为每质量调整生命年20000英镑。作者认为若价格低于约200英镑/完全保护者,RSV疫苗和抗体策略可能具成本效果,季节性接种可能提供最直接获益。
要点
- RSV每年每100名5岁以下儿童导致12次初级保健就诊和0.9次住院,负担主要集中于6月龄以下婴儿。
- 最具成本效果的策略是选择性免疫所有在RSV流行季开始前出生的儿童,疫苗最高价格220英镑(95%UI 208-232)。
- 无季节性限制的婴儿、新生儿和孕妇策略每完全保护者的最高支付价格分别为192、81和54英镑。
核心结论
- RSV导致的初级保健就诊次数和住院次数分别约为流感的近2倍和近5倍。
- RSV疫苗和抗体策略若价格低于约200英镑/完全保护者,可能具成本效果。
- 季节性接种策略可能提供最直接获益;群体效应可能使全年婴儿接种策略更具吸引力,但目前尚不清楚此类规划是否会产生群体效应。
研究设计与样本
- 研究采用多变量回归分析估计英格兰5岁以下儿童RSV疾病负担,并基于结果评估不同RSV免疫策略(婴儿接种、孕妇接种或新生儿预防性抗体)的潜在效果。
- 对上述策略分别或同时实施进行成本效果分析,并评估将接种限制在一年中特定月份的效果。
- 研究由英国国家卫生研究院(UK National Institute for Health Research)资助。
主要发现
- 估计RSV每年每100名5岁以下儿童导致12次初级保健就诊(95%CI 11.9-12.1)和0.9次住院(95%CI 0.89-0.90),主要负担发生于6月龄以下婴儿。
- 最具成本效果的策略是选择性免疫所有在RSV流行季开始前出生的儿童,疫苗最高价格为220英镑(95%不确定性区间208-232),增量成本效果比为每质量调整生命年20000英镑。
- 无季节性限制的婴儿、新生儿和孕妇策略每完全保护者的最高支付价格分别为192英镑(95%UI 168-219)、81英镑(76-86)和54英镑(51-57)。
关键数值与推荐
- 最具成本效果策略的疫苗最高价格为220英镑(95%UI 208-232),对应增量成本效果比每质量调整生命年20000英镑。
- 无季节性限制的婴儿策略每完全保护者最高支付价格192英镑(95%UI 168-219)。
- 无季节性限制的新生儿策略每完全保护者最高支付价格81英镑(95%UI 76-86)。
- 无季节性限制的孕妇策略每完全保护者最高支付价格54英镑(95%UI 51-57)。
临床怎么用
- 作者认为,RSV疫苗和抗体策略若价格低于约200英镑/完全保护者,可能具成本效果。
- 作者认为,季节性接种策略可能提供最直接获益。
- 作者指出,群体效应可能使全年婴儿接种策略更具吸引力,但目前尚不清楚此类规划是否会产生群体效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in development and likely to be available in the next 5-10 years. The most efficient way to use these products when they become available is an important consideration for public health decision makers. METHODS: We performed a multivariate regression analysis to estimate the burden of RSV in children younger than 5 years in England (UK), a representative high-income temperate country, and used these results to assess the potential effect of different RSV immunisation strategies (targeting vaccination for infants, or pregnant women, or prophylactic antibodies for neonates). We did a cost-effectiveness analysis for these strategies, implemented either separately or concurrently, and assessed the effect of restricting vaccination to certain months of the year. FINDINGS: We estimated that RSV is responsible for 12 primary care consultations (95% CI 11·9-12·1) and 0·9 admissions to hospital annually per 100 children younger than 5 years (95% CI 0·89-0·90), with the major burden occurring in infants younger than 6 months. The most cost-effective strategy was to selectively immunise all children born before the start of the RSV season (maximum price of £220 [95% uncertainty interval (UI) 208-232] per vaccine, for an incremental cost-effectiveness ratio of £20 000 per quality-adjusted life-year). The maximum price per fully protected person that should be paid for the infant, newborn, and maternal strategies without seasonal restrictions was £192 (95% UI 168-219), £81 (76-86), and £54 (51-57), respectively. INTERPRETATION: Nearly double the number of primary care consultations, and nearly five times the number of admissions to hospital occurred with RSV compared with influenza. RSV vaccine and antibody strategies are likely to be cost-effective if they can be priced below around £200 per fully protected person. A seasonal vaccination strategy is likely to provide the most direct benefits. Herd effects might render a year-round infant vaccination strategy more appealing, although it is currently unclear whether such a programme would induce herd effects. FUNDING: UK National Institute for Health Research.
引用
- Cromer D, van Hoek AJ, Newall AT, et al. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017. PMID: 28804787. doi:10.1016/S2468-2667(17)30103-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。